TY - JOUR
T1 - High Prevalence of Celiac Disease Among Danish Adolescents
T2 - A Population-based Study
AU - Crawley, Caecilie
AU - Sander, Stine Dydensborg
AU - Nohr, Ellen Aagaard
AU - Lillevang, Søren Thue
AU - Andersen, Anne Marie Nybo
AU - Murray, Joseph
AU - Husby, Steffen
N1 - Funding Information:
J.M. has received study grants from Nexpep/ImmusanT, National Institutes of Health, Immunogenix, Takeda Pharmaceutical, Allakos, Oberkotter, and Cour; consultancy fees from Bionix, Lilly Research Laboratory, Johnson & Johnson, Dr. Schar USA, UCB Biopharma, Celimmune, Intrexon Corporation, Chugai Pharma, Kanyos, and Boehringer Ingelheim. J.M. holds patents licensed to Evelo Biosciences and receives royalties from Torax Medical. The remaining authors report no conflicts of interest.
Funding Information:
This project was funded by the A.P. M?ller Fund (grant nos.19-L-0228 and 18-L-0032), Odense University Hospital Research Fund (A3675 and A2971), Direkt?r Kurt B?nnelyckes og hustru Fru Grethe B?nnelyckes Fund (100 53030), Torben og Alice Frimodts Fund (n/a), and L.F. Foghts Fund (21.844) to C.C. and the Augustinus Fund (19-2419) to S.H. Thermo Fischer (n/a) donated $70,000 and had no influence on the design of the study. C.C. holds a PhD grant funded by University of Southern Denmark, the Region of Southern Denmark, and Hans Christian Andersen Children?s Hospital. The Department of Clinical Immunology, Odense University Hospital covered the cost of the Celiac screening analysis.
Funding Information:
The Danish National Birth cohort was established with a significant grant from the Danish National Research Foundation. Additional support was obtained from the Danish Regional Committees, the Pharmacy Foundation, the Egmont Foundation, the March of Dimes Birth Defects Foundation, the Health Foundation, and other minor grants. The Danish National Birth Cohort's Biobank has been supported by the Novo Nordisk Foundation and the Lundbeck Foundation.
Funding Information:
This project was funded by the A.P. Møller Fund (grant nos.19-L-0228 and 18-L-0032), Odense University Hospital Research Fund (A3675 and A2971), Direktør Kurt Bønnelyckes og hustru Fru Grethe Bønnelyckes Fund (100 53030), Torben og Alice Frimodts Fund (n/a), and L.F. Foghts Fund (21.844) to C.C. and the Augustinus Fund (19-2419) to S.H. Thermo Fischer (n/a) donated $70,000 and had no influence on the design of the study. C.C. holds a PhD grant funded by University of Southern Denmark, the Region of Southern Denmark, and Hans Christian Andersen Children's Hospital. The Department of Clinical Immunology, Odense University Hospital covered the cost of the Celiac screening analysis.
Publisher Copyright:
Copyright © 2021 by European Society for Pediatric Gastroenterology, Hepatology, and Nutrition and North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition.
PY - 2022/1/1
Y1 - 2022/1/1
N2 - Objectives: The objective of this study was to establish an unselected cohort of Danish adolescents and estimate the prevalence of undiagnosed celiac disease (CeD). Methods: The Glutenfunen cohort participants were recruited from an unselected subsample of the Danish National Birth Cohort, defined as participants living in the Island of Funen, Denmark. We invited all 7431 eligible participants in the age range of 15 to 21 years to a clinical visit. CeD diagnosis was based on screening with IgA transglutaminase antibodies (TG2-IgA) and if positive, was followed by duodenal biopsies compatible with CeD (Marsh 2–3). We calculated the prevalence of CeD in the Glutenfunen cohort as the number of CeD cases diagnosed before and during the study divided by the number of participants in the Glutenfunen cohort. Results: We included 1266 participants in the Glutenfunen cohort (17%, 1266/7431). 1.1% (14 of 1266 participants) had CeD diagnosed before entering the cohort and based on the Danish National Patient Register, 0.2% of the nonparticipants (14 of 6165) had a diagnosis of CeD. In total, 2.6% (33 participants) had TG2 IgA above the upper limit of normal. Nineteen participants had duodenal biopsies compatible with CeD. The prevalence of CeD in the Glutenfunen cohort was 2.6% [(14 þ 19)/1266]. Conclusions: Our study suggests that CeD is much more common than expected among Danish adolescents, comparable to other European countries, and that the majority were asymptomatic or oligosymptomatic and were only found because of the screening procedure.
AB - Objectives: The objective of this study was to establish an unselected cohort of Danish adolescents and estimate the prevalence of undiagnosed celiac disease (CeD). Methods: The Glutenfunen cohort participants were recruited from an unselected subsample of the Danish National Birth Cohort, defined as participants living in the Island of Funen, Denmark. We invited all 7431 eligible participants in the age range of 15 to 21 years to a clinical visit. CeD diagnosis was based on screening with IgA transglutaminase antibodies (TG2-IgA) and if positive, was followed by duodenal biopsies compatible with CeD (Marsh 2–3). We calculated the prevalence of CeD in the Glutenfunen cohort as the number of CeD cases diagnosed before and during the study divided by the number of participants in the Glutenfunen cohort. Results: We included 1266 participants in the Glutenfunen cohort (17%, 1266/7431). 1.1% (14 of 1266 participants) had CeD diagnosed before entering the cohort and based on the Danish National Patient Register, 0.2% of the nonparticipants (14 of 6165) had a diagnosis of CeD. In total, 2.6% (33 participants) had TG2 IgA above the upper limit of normal. Nineteen participants had duodenal biopsies compatible with CeD. The prevalence of CeD in the Glutenfunen cohort was 2.6% [(14 þ 19)/1266]. Conclusions: Our study suggests that CeD is much more common than expected among Danish adolescents, comparable to other European countries, and that the majority were asymptomatic or oligosymptomatic and were only found because of the screening procedure.
KW - Coeliac autoimmunity
KW - Epidemiology
KW - Gluten
KW - Immunology
KW - Screening
UR - http://www.scopus.com/inward/record.url?scp=85119688434&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119688434&partnerID=8YFLogxK
U2 - 10.1097/MPG.0000000000003247
DO - 10.1097/MPG.0000000000003247
M3 - Article
C2 - 34310439
AN - SCOPUS:85119688434
SN - 0277-2116
VL - 74
SP - 85
EP - 90
JO - Journal of Pediatric Gastroenterology and Nutrition
JF - Journal of Pediatric Gastroenterology and Nutrition
IS - 1
ER -